2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1813

Evaluation Of The Effect Of Sildenafil On The Microvascular Blood Flow and On The Endothelial Progenitor Cells In Patients With Early Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 1310

Evaluation Of The Japanese Patients With Rheumatoid Arthritis (RA) Of Rapid Radiographic Progression (RRP) Treated With Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) In Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (an interim report of Apple Survey)
Abstract Number: 1810

Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort
Abstract Number: 135

Evaluation Of The Quality Of Life and Sleep In Patients With Benign Joint Hypermobility Syndrome
Abstract Number: 2433

Evaluation Of The Two-Step Referral Strategy For Axial Spondyloarthritis In The Spondyloarthritis Caught Early Cohort
Abstract Number: 1324

Evaluation Of The Usefulness Of Interferon-Gamma Release Assays and Tuberculin Skin Test For Detection Of Latent Mycobacterium Tuberculosis Infection In Korean Rheumatic Patients With Biologic Agents
Abstract Number: 525

Evidence For Enhanced Induction Of Unfolded Protein Response Target Genes In Peripheral Blood Mononuclear Cells From Spondyloarthritis Patients
Abstract Number: 2058

Evidence For Immunotherapy In Polymyositis and Dermatomyositis: A Systematic Review
Abstract Number: 542

Evidence For Involvement Of C5a Receptor in Human and Murine Lupus Nephritis
Abstract Number: 2497

Evidence Of a Microbial Signature In The Intestinal Microbiome In Ankylosing Spondylitis
Abstract Number: 2692

Evidence That Fat Metaplasia Is a Key Intermediary In The Development Of Sacroiliac Joint Ankylosis Following Repair Of Erosions In Patients With Spondyloarthritis
Abstract Number: 2741

Evidence That STAT3 controls NLRP3 inflammasome–dependent Release Of IL-1β and Pyronecrosis Through Regulation of mitochondrial activity
Abstract Number: 1643

Ex Vivo Suppression Of RA Effector T Cells (Teff) By Mapc Media Is Synergistic With Treg
Abstract Number: 639

Examination Of The Cytokine Profile Of The Cerebrospinal Fluid In Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 259

Examining Patient Reported Outcome Measurement Information System Measures In Community Dwelling Adults With Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].